GDMT includes the major “pillars” of heart failure therapy, such as beta-blockers, angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) or angiotensin receptor–neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), and sodium–glucose co-transporter-2 inhibitors (SGLT2-inhibitors) [11]. The gene discussed is ACE; the disease is heart failure.